Scheduled Drugs Regulation (Alta. Reg. 66/2007)

Alta. Reg. 66/2007

Alberta — Regulations

© Published by Alberta King’s Printer Alberta King’s Printer Suite 700, Park Plaza 10611 - 98 Avenue Edmonton, AB T5K 2P7 Phone: 780-427-4952 E-mail: kings-printer@gov.ab.ca Shop on-line at kings-printer.alberta.ca Province of Alberta Office Consolidation Alberta Regulation 66/2007 With amendments up to and including Alberta Regulation 4/2023 Current as of January 11, 2023 PHARMACY AND DRUG ACT SCHEDULED DRUGS REGULATION

Copyright and Permission Statement The Government of Alberta, through the Alberta King’s Printer, holds copyright for all Alberta legislation. Alberta King’s Printer permits any person to reproduce Alberta’s statutes and regulations without seeking permission and without charge, provided due diligence is exercised to ensure the accuracy of the materials produced, and copyright is acknowledged in the following format: © Alberta King’s Printer, 20__.* *The year of first publication of the legal materials is to be completed.

Note All persons making use of this consolidation are reminded that it has no legislative sanction, that amendments have been embodied for convenience of reference only. The official Statutes and Regulations should be consulted for all purposes of interpreting and applying the law.

(Consolidated up to 4/2023) ALBERTA REGULATION 66/2007 Pharmacy and Drug Act SCHEDULED DRUGS REGULATION Table of Contents 1

Schedule 1 drugs 2

Schedule 2 drugs 3

Schedule 3 drugs 4 Repeal 6 Coming into force

Schedule 1 drugs 1(1) Subject to subsection (2), the following drugs are designated as

Schedule 1 drugs for the purposes of

section 31(1)(

c) of the Pharmacy and Drug Act: (

a) drugs set out in

Schedule I of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities, other than drugs described in

section 31(1)(

a) or (

b) of the Act; (

b) vaccines for diphtheria, t etanus, pertussis, polio, haemophilus B, measles, meningitis, mumps, rubella and pediatric hepatitis B; (

c) diacetylmorphine; (

d) fentanyl, remifentanil, suf entanil and any other fentanyl analogues; (

e) hydromorphone; (

f) morphine; (

g) oxycodone.

(2) A drug referred to in subsection (1)(c), (d), (e), (

f) or (

g) shall be excluded from the designation if the drug (

a) is included in any

schedule to the Controlled Drugs and Substances Act (Canada) unless the drug is authorized

Section 2 AR 66/2007 SCHEDULED DRUGS REGULATION 2 under the Controlled Drugs and Substances Act (Canada) for administration or sale to a person without a prescription, or (

b) subject to subsection (3), is on the Prescription Drug Lis t.

(3) If a drug referred to in subsection (1)(c), (d), (e), (

f) or (

g) has uses that are excluded from the Prescription Drug List, the designation under subsection (1) shall be only for the excluded uses of that drug. AR 66/2007 s1;61/2016;11/2017;4/2023

Schedule 2 drugs 2(1) Subject to subsection (2), the following drugs are designated as

Schedule 2 drugs for the purposes of

section 32(1)(

a) of the Pharmacy and Drug Act: (

a) the drugs set out in

Schedule II of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities; (

b) iodinated casein; (b.1) repealed AR 11/2017 s3; (

c) repealed AR 34/2012 s2.

(2) The following drugs are excluded from the designation under subsection (1)(a): (

a) vaccines for diphtheria, t etanus, pertussis, polio, haemophilus B, measles, meningitis, mumps, rubella and pediatric hepatitis B; (

b) diphenhydramine and its salts for topical use; (

c) charcoal (activated) for use in poisoning treatment; (

d) hydroquinone (topical preparations in concentrations of less than 2%); (

e) naloxone and its salts, whe n indicated for emergency use for opioid overdose outside hospital settings. AR 66/2007 s2;34/2012;61/2016;11/2017

Schedule 3 drugs 3(1) Subject to subsection (2), the following drugs are designated as

Schedule 3 drugs for the purposes of

section 33(1) of the Pharmacy and Drug Act:

Section 3 AR 66/2007 SCHEDULED DRUGS REGULATION 3 (

a) the drugs set out in

Schedule III of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities; (

b) drugs for veterinary use that are to be administered by injection.

(2) The following drugs are excluded from the designation under subsection (1): (

a) acetaminophen (in sustai ned release formulations); (

b) acetylsalicylic acid and its salts (in products for oral, adult use, in strengths of 81 mg/dosage unit and 650 mg or greater/dosage unit and in rectal preparations containing more than 150 mg/dosage unit); (

c) aloe vera latex, its extr acts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg/dosage unit); (

d) aluminum oxide; (

e) anetholtrithione; (

f) antazoline and its salts; (

g) antipyrine (for otic use); (

h) benzonatate; (

i) berberis vulgaris (barberry); (

j) brompheniramine and its salts; (

k) calcium polycarbophil; (

l) carbinoxamine and its salts; (

m) casanthranol; (

n) cerapon; (

o) chlophendianol and its salts; (

p) chlorzoxazone and its salts; (

q) clemastine and its salts; (

r) danthron;

Section 3 AR 66/2007 SCHEDULED DRUGS REGULATION 4 (

s) dehydrocholic acid and its salts; (

t) deoxycholic acid and its salts; (

u) dexbrompheniramine and its salts; (

v) dextromethorphan and its salts; (

w) repealed AR 34/2012 s2; (

x) dimethothiazine; (

y) diphenhydramine and its salts and preparations; (

z) diphenylpyraline; (aa) doxylamine and its salts (ex cept those sold for nausea and vomiting related to pregnancy); (bb) electrolyte solutions for oral hydration; (cc) fractar; (dd) glyceroargentinate; (ee) haloprogin; (ff) iodine and its salts and d erivatives (for topical use); (gg) lactic acid; (hh) lactulose; (ii) loratadine and its salts and preparations; (jj) magnesium citrate (cathartics); (kk) magnesium salicylate (ex cept oral dosage forms which also contain choline salicylate); (ll) narcotine and it s salts (Noscapine); (mm) oxethazine; (nn) phenyltoloxamine and its salts; (oo) povidone-iodine (vaginal and topical preparations); (pp) promethazine and its salts (for topical use); (qq) ephedrine and its salts in combination products (for use in treatment of nasal congestion, in strengths of no more that 8 mg/dosage unit and with a label recommending a

Section 4 AR 66/2007 SCHEDULED DRUGS REGULATION 5 maximum treatment of 7 days of not more than 8 mg/dose and 32 mg/day); (rr) pseudoephedrine and its salts and preparations in combination products; (ss) sodium biphosphate (cathartics); (tt) sodium phosphate (cathartics); (uu) triethanolamine oleate; (vv) triethanolamine salicylate (in concentrations greater than 20%); (ww) tripelennamine and its salts; (xx) triprolidine; (yy) tyrothricine. AR 66/2007 s3;34/2012 Repeal 4 The Scheduled Drugs Regulation (AR 86/2002) is repealed on the coming into force of

section 34 of the Pharmacy and Drug Act. 5 Repealed AR 109/2016 s2. Coming into force 6 This Regulation comes into force on the coming into force of

section 34 of the Pharmacy and Drug Act.

Printed on Recycled Paper *9780779838622*

Document details

Collection	Alberta — Regulations
Citation	Alta. Reg. 66/2007
Type	regulation
Volume / chapter	2007 066
Language	en
Format	pdf
Source	PROVINCIAL
Identifier	561be0c0c5029ced8bd7d5752f3a81a5857c5957

Source file is stored in the law ingest library (pdf).